The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver. * Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm. * Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention * Daily log to be completed for tracking peanut consumption * 2-day Dietary recall at baseline, during Week 6 and Week 12 * Poat intervention Fibro scans for participants with baseline scans available
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
125
MASLD patients will consume 50 gm of peanut daily for 12 weeks
Henry Ford Health System
Detroit, Michigan, United States
RECRUITINGHepatic Markers
Changes in hepatic markers such as ALT, ASP, ALP will be evaluated through blood tests at baseline and post-intervention
Time frame: Baseline to post-intervention (12 weeks)
Metabolic Profile
Investigate change in metabolic profiles i.e., total cholesterol, HDL-C, LDL-C, triglycerides, glucose, hemoglobin A1C (HBA1C), and insulin over 12 weeks
Time frame: Baseline to post-intervention (12 weeks)
Gut microbiota composition
Investigate whether MASLD patients in the Peanut arm will have improved gut microbiota compositions than those in the Control arm
Time frame: Baseline to post-intervention (12 weeks)
Intrahepatic fat content
Explore whether MASLD patients in the Peanut arm may have lower intrahepatic fat content (IHF) than those in the Control arm over 12 weeks
Time frame: Baseline to post-intervention (12 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.